PRT811 Showcases Early Signals of Efficacy in IDH-Mutant Glioma and Uveal Melanoma
Source: OncLive, July 2023
Varun Monga, MBBS, discusses the mechanism of action of PRT811, key efficacy and safety findings from a phase 1 trial investigating the agent, and potential future directions with this agent in uveal melanoma and IDH-mutant high-grade glioma.
Phase 1 research indicates that continued investigation with the protein arginine methyltransferase 5 (PRMT5) brain penetrant PRT811 may bolster the uveal melanoma and IDH-mutant high-grade glioma treatment paradigms, addressing unmet needs for these patient populations, according to Varun Monga, MBBS.
At the 2023 ASCO Annual Meeting, Monga presented findings from a phase 1 trial (NCT04089449) investigating PRT811 in these populations. In this trial, 2 patients in the glioma cohort (n = 38) responded to treatment, and both patients had IDH-positive disease. One of these patients achieved a complete response (CR) with a duration of response (DOR) of 31.0 months and was still receiving treatment at the data cutoff date, and the other patient had a CR with a DOR of 7.5 months and subsequently developed progressive disease (PD). In the uveal melanoma cohort (n = 23), 1 patient with splicing mutation–positive disease responded to the agent, achieving a partial response (PR) with a DOR of 10.0 months followed by PD.